Publikasi Scopus 2024 per tanggal 31 Juli 2024 (607 artikel)

Lee K.H.; Jiamsakul A.; Kiertiburanakul S.; Borse R.; Khol V.; Yunihastuti E.; Azwa I.; Ketut Agus Somia I.; Chaiwarith R.; Pham T.N.; Khusuwan S.; Do C.D.; Kumarasamy N.; Gani Y.; Ditangco R.; Ng O.T.; Pujari S.; Lee M.P.; Avihingsanon A.; Chen H.-P.; Zhang F.; Tanuma J.; Ross J.; Choi J.Y.
Lee, Ki Hyun (57223989176); Jiamsakul, Awachana (55285745500); Kiertiburanakul, Sasisopin (6506539792); Borse, Rohidas (59198920300); Khol, Vohith (57188842644); Yunihastuti, Evy (57221273925); Azwa, Iskandar (55553159100); Ketut Agus Somia, I. (58145407800); Chaiwarith, Romanee (13806165200); Pham, Thach Ngoc (57213330022); Khusuwan, Suwimon (56166613100); Do, Cuong Duy (56658396600); Kumarasamy, Nagalingeswaran (7003549856); Gani, Yasmin (57188842533); Ditangco, Rossana (55406840800); Ng, Oon
57223989176; 55285745500; 6506539792; 59198920300; 57188842644; 57221273925; 55553159100; 58145407800; 13806165200; 57213330022; 56166613100; 56658396600; 7003549856; 57188842533; 55406840800; 59091740100; 57205894660; 59164277600; 57196347321; 59198669900; 55503803800; 57208428839; 57193109926; 59198670000
Risk factors for toxoplasmosis in people living with HIV in the Asia-Pacific region
2024
PLoS ONE
19
45480
e0306245
0
Department of Internal Medicine, AIDS Research Institute, Yonsei University College of Medicine, Seoul, South Korea; The Kirby Institute, UNSW Sydney, Kensington, NSW, Australia; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; BJ Government Medical College, Sassoon General Hospital, Pune, India; National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Infectious Diseases Unit, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Faculty of Medicine, Udayana University, Prof. Dr. I.G.N.G. Ngoerah Hospital, Bali, Indonesia; Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; National Hospital for Tropical Diseases, Hanoi, Viet Nam; Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; Bach Mai Hospital, Hanoi, Viet Nam; CART CRS, Voluntary Health Services, Chennai, India; Hospital Sungai Buloh, Sungai Buloh, Malaysia; Research Institute for Tropical Medicine, Muntinlupa City, Philippines; National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore; Institute of Infectious Diseases, Pune, India; Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong; HIV-NAT/ Thai Red Cross AIDS Research Centre, Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Taipei Veterans General Hospital, Taipei, Taiwan; Beijing Ditan Hospital, Capital Medical University, Beijing, China; National Center for Global Health and Medicine, Tokyo, Japan; TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand
Lee K.H., Department of Internal Medicine, AIDS Research Institute, Yonsei University College of Medicine, Seoul, South Korea; Jiamsakul A., The Kirby Institute, UNSW Sydney, Kensington, NSW, Australia; Kiertiburanakul S., Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Borse R., BJ Government Medical College, Sassoon General Hospital, Pune, India; Khol V., National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Yunihastuti E., Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Azwa I., Infectious Diseases Unit, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Ketut Agus Somia I., Faculty of Medicine, Udayana University, Prof. Dr. I.G.N.G. Ngoerah Hospital, Bali, Indonesia; Chaiwarith R., Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; Pham T.N., National Hospital for Tropical Diseases, Hanoi, Viet Nam; Khusuwan S., Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; Do C.D., Bach Mai Hospital, Hanoi, Viet Nam; Kumarasamy N., CART CRS, Voluntary Health Services, Chennai, India; Gani Y., Hospital Sungai Buloh, Sungai Buloh, Malaysia; Ditangco R., Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Ng O.T., National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore; Pujari S., Institute of Infectious Diseases, Pune, India; Lee M.P., Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong; Avihingsanon A., HIV-NAT/ Thai Red Cross AIDS Research Centre, Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Chen H.-P., Taipei Veterans General Hospital, Taipei, Taiwan; Zhang F., Beijing Ditan Hospital, Capital Medical University, Beijing, China; Tanuma J., National Center for Global Health and Medicine, Tokyo, Japan; Ross J., TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; Choi J.Y., Department of Internal Medicine, AIDS Research Institute, Yonsei University College of Medicine, Seoul, South Korea
Introduction Toxoplasma gondii can cause symptomatic toxoplasmosis in immunodeficient hosts, including in people living with human immunodeficiency virus (PLWH), mainly because of the reactivation of latent infection. We assessed the prevalence of toxoplasmosis and its associated risk factors in PLWH in the Asia-Pacific region using data from the TREAT Asia Human Immunodeficiency Virus (HIV) Observational Database (TAHOD) of the International Epidemiology Databases to Evaluate AIDS (IeDEA) Asia-Pacific. Methods This study included both retrospective and prospective cases of toxoplasmosis reported between 1997 and 2020. A matched case-control method was employed, where PLWH diagnosed with toxoplasmosis (cases) were each matched to two PLWH without a toxoplasmosis diagnosis (controls) from the same site. Sites without toxoplasmosis were excluded. Risk factors for toxoplasmosis were analyzed using conditional logistic regression. Results A total of 269/9576 (2.8%) PLWH were diagnosed with toxoplasmosis in 19 TAHOD sites. Of these, 227 (84%) were reported retrospectively and 42 (16%) were prospective diagnoses after cohort enrollment. At the time of toxoplasmosis diagnosis, the median age was 33 years (interquartile range 28–38), and 80% participants were male, 75% were not on antiretroviral therapy (ART). Excluding 63 out of 269 people without CD4 values, 192 (93.2%) had CD4 ≤200 cells/μL and 162 (78.6%) had CD4 ≤100 cells/μL. By employing 538 matched controls, we found that factors associated with toxoplasmosis included abstaining from ART (odds ratio [OR] 3.62, 95% CI 1.81–7.24), in comparison to receiving nucleoside reverse transcriptase inhibitors plus non-nucleoside reverse transcriptase inhibitors, HIV exposure through injection drug use (OR 2.27, 95% CI 1.15–4.47) as opposed to engaging in heterosexual intercourse and testing positive for hepatitis B virus surface antigen (OR 3.19, 95% CI 1.41–7.21). Toxoplasmosis was less likely with increasing CD4 counts (51–100 cells/μL: OR 0.41, 95% CI 0.18–0.96; 101–200 cells/μL: OR 0.14, 95% CI 0.06–0.34; >200 cells/μL: OR 0.02, 95% CI 0.01–0.06), when compared to CD4 ≤50 cells/μL. Moreover, the use of prophylactic cotrimoxazole was not associated with toxoplasmosis. Conclusions Symptomatic toxoplasmosis is rare but still occurs in PLWH in the Asia-Pacific region, especially in the context of delayed diagnosis, causing advanced HIV disease. Immune reconstitution through early diagnosis and ART administration remains a priority in Asian PLWH. Copyright: © 2024 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Adult; Asia; Case-Control Studies; Female; HIV Infections; Humans; Male; Middle Aged; Prevalence; Prospective Studies; Retrospective Studies; Risk Factors; Toxoplasma; Toxoplasmosis; CD4 antigen; cotrimoxazole; hepatitis B surface antigen; nonnucleoside reverse transcriptase inhibitor; adult; antiretroviral therapy; Article; Asian; CD4 lymphocyte count; controlled study; delayed diagnosis; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; immune deficiency; major clinical study; male; prevalence; risk factor; sexual intercourse; toxoplasmosis; virus load; Asia; case control study; complication; epidemiology; female; middle aged; prospective study; retrospective study; Toxoplasma; toxoplasmosis
Public Library of Science
19326203
38950027
Article
Q1
885
5108